GENINUS, Inc. engages in the research and development of NGS (Next Generation Sequencing)-based genome analysis technology and solutions. Its products include the following: CancerSCAN, an NGS cancer diagnosis service; LiquidSCAN, a liquid biopsy NGS test; Celinus, a single-cell genome analysis service; and HealthSCAN, a genetic testing service that tests innate genes to identify diseases that each person is vulnerable to. The company was founded on April 20, 2018 and is headquartered in Seoul, South Korea.